PT - JOURNAL ARTICLE AU - Kshirsagar, Meghana AU - Mukherjee, Sumit AU - Nasir, Md AU - Becker, Nicholas AU - Ferres, Juan Lavista AU - Richardson, Barbra A. TI - Risk of hospitalization and mortality after breakthrough SARS-CoV-2 infection by vaccine type and previous SARS-CoV-2 infection utilizing medical claims data AID - 10.1101/2021.12.08.21267483 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.08.21267483 4099 - http://medrxiv.org/content/early/2021/12/09/2021.12.08.21267483.short 4100 - http://medrxiv.org/content/early/2021/12/09/2021.12.08.21267483.full AB - We compare the risks of hospitalization (n=1121) and mortality (n=138) in a cohort of 17,881 breakthrough SARS-CoV-2 infections for the Pfizer, Moderna and Janssen vaccines for those with and without SARS-CoV-2 infections prior to vaccination. Cox regression analysis results in a lower hazard ratio for those receiving the Moderna vaccine, but a significantly higher hazard ratio for those receiving the Janssen vaccine, as compared to those who got the Pfizer vaccine. Importantly, the risk of hospitalization (P<0.001) and death (P<0.05) were lower among individuals who had a SARS-CoV-2 infection prior to vaccination, independent of age, sex, comorbidities, and vaccine type.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval and consent to participate This study does not constitute as human subjects research due to the usage and reporting of only deidentified observational data as determined by the ethics committee of the University of Washington School of Medicine. An ethics approval waiver and a consent waiver were received from the ethics committee of the University of Washington School of Medicine. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors